Mark Mcdade, Director at Five Prime Therapeutics, holds 0.00 shares in Five Prime Therapeutics (Ticker: FPRX), holds 0.00 shares in Icosavax (Ticker: ICVX), holds 742.21K shares in Tourmaline Bio (Ticker: TRML). Most recently, Mark Mcdade ― shares of Five Prime Therapeutics on ― for an estimated value of ―.
Mark Mcdade latest transaction was an Uninformative Buy of ―.
What was Mark Mcdade's most profitable transaction?
Mark Mcdade’s most profitable transaction was an Informative Buy of ICVX stock on April 5, 2022. The return on the trade was -3.80%.
What is Mark Mcdade's role in Five Prime Therapeutics?
Mark Mcdade's role in Five Prime Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.